Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -28,630.77
- Piotroski Score 1.00
- Grade Buy
- Symbol (INKT)
- Company MiNK Therapeutics, Inc.
- Price $0.68
- Changes Percentage (-0.6%)
- Change -$0
- Day Low $0.67
- Day High $0.71
- Year High $1.90
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.59
- Trailing P/E Ratio -1.63
- Forward P/E Ratio -1.63
- P/E Growth -1.63
- Net Income $-22,457,859
Income Statement
Quarterly
Annual
Latest News of INKT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Large parts of adult social care market in England face collapse, thinktank warns
The Nuffield Trust warns that adult social care sector in England faces collapse due to £2.8bn cost burden from tax and wage rises, risking vulnerable people. Urgent financial support is needed to st...
By The Guardian | 16 hours ago -
Muslims face 'bleak and dystopian' climate in UK, says head of thinktank
Shabna Begum warns that if Islamophobia continues to be tolerated in politics, it will fuel racist riots in the UK. She criticizes the divisive rhetoric towards Muslims and calls for a change in polit...
By The Guardian | 5 days ago -
Trump tariffs would halve UK growth and push up prices, says thinktank
NIESR warns of UK economic harm if Trump's protectionist policies are implemented. Potential tariffs could halve UK growth, increase inflation, and raise interest rates. Budget measures may not suffic...
By The Guardian | 2 weeks ago
